首页 > 最新文献

Journal of Korean Medical Science最新文献

英文 中文
Optimal Antithrombotic Therapy Beyond 1-Year After Coronary Revascularization in Patients With Atrial Fibrillation. 心房颤动患者冠状动脉血运重建术后 1 年后的最佳抗血栓治疗。
IF 3 3区 医学 Q1 Medicine Pub Date : 2024-06-24 DOI: 10.3346/jkms.2024.39.e191
Jihoon Kim, Danbee Kang, Hyunsoo Kim, Hyejeong Park, Taek Kyu Park, Joo Myung Lee, Jeong Hoon Yang, Young Bin Song, Jin-Ho Choi, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Eliseo Guallar, Juhee Cho, Joo-Yong Hahn

Background: Currently, non-vitamin K-antagonist oral anticoagulant (NOAC) monotherapy has been suggested as the optimal antithrombotic therapy for atrial fibrillation (AF) beyond one year after coronary revascularization. The aim of this study was to compare the outcomes between NOAC monotherapy and NOAC plus antiplatelet combination therapy using real-world data.

Methods: Between 2015 and 2020, patients with AF who had received NOACs beyond one year after coronary revascularization were enrolled from Korean national insurance data. We emulated a pragmatic sequence of trials between the NOAC monotherapy and the antiplatelet combination therapy followed by propensity score matching. The primary endpoint was major adverse cardiac and cerebrovascular events (MACCEs), a composite of all-cause death, myocardial infarction, and stroke.

Results: Among 206,407 person-trials from 4,465 individuals, we compared 3,275 pairs of the monotherapy and the matched combination therapy. During a median follow-up of 1.24 years, the incidence rate of MACCE was 19.4% and 20.0% per patient-year in the monotherapy group and the antiplatelet combination group, respectively (hazard ratio [HR], 0.96; 95% confidence interval [CI], 0.88-1.05; P = 0.422). Compared with the antiplatelet combination group, the monotherapy group had a significantly lower incidence rate of major bleeding, defined as intracranial bleeding or gastrointestinal bleeding requiring hospitalization (2.8% vs. 3.6% per patient-year; HR, 0.78; 95% CI, 0.62-0.97; P = 0.024).

Conclusion: As an antithrombotic therapy for AF beyond one year after coronary revascularization, NOAC monotherapy was associated with a similar risk of MACCE and a lower risk of major bleeding compared to NOAC plus antiplatelet combination therapy.

背景:目前,非维生素 K-拮抗剂口服抗凝剂(NOAC)单药疗法被认为是冠状动脉血运重建术后一年内治疗心房颤动(AF)的最佳抗血栓疗法。本研究旨在利用真实世界的数据,比较 NOAC 单药治疗和 NOAC 加抗血小板联合治疗的疗效:方法:2015 年至 2020 年间,我们从韩国国家保险数据中选取了冠状动脉血运重建术后一年内接受过 NOACs 治疗的房颤患者。我们模仿了 NOAC 单药治疗和抗血小板联合治疗之间的务实试验顺序,然后进行倾向评分匹配。主要终点是主要心脏和脑血管不良事件(MACCEs),即全因死亡、心肌梗死和中风的综合结果:在来自 4465 名患者的 206,407 人次试验中,我们对 3275 对单一疗法和匹配的联合疗法进行了比较。在中位 1.24 年的随访期间,单一疗法组和抗血小板联合疗法组每名患者每年的 MACCE 发生率分别为 19.4% 和 20.0%(危险比 [HR],0.96;95% 置信区间 [CI],0.88-1.05;P = 0.422)。与抗血小板联合治疗组相比,单药治疗组的大出血发生率显著降低,大出血是指需要住院治疗的颅内出血或消化道出血(每患者每年2.8%对3.6%;HR,0.78;95% CI,0.62-0.97;P = 0.024):结论:作为冠状动脉血运重建术后一年以上的房颤抗栓疗法,NOAC单药治疗与NOAC加抗血小板联合治疗相比,MACCE风险相似,大出血风险较低。
{"title":"Optimal Antithrombotic Therapy Beyond 1-Year After Coronary Revascularization in Patients With Atrial Fibrillation.","authors":"Jihoon Kim, Danbee Kang, Hyunsoo Kim, Hyejeong Park, Taek Kyu Park, Joo Myung Lee, Jeong Hoon Yang, Young Bin Song, Jin-Ho Choi, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Eliseo Guallar, Juhee Cho, Joo-Yong Hahn","doi":"10.3346/jkms.2024.39.e191","DOIUrl":"10.3346/jkms.2024.39.e191","url":null,"abstract":"<p><strong>Background: </strong>Currently, non-vitamin K-antagonist oral anticoagulant (NOAC) monotherapy has been suggested as the optimal antithrombotic therapy for atrial fibrillation (AF) beyond one year after coronary revascularization. The aim of this study was to compare the outcomes between NOAC monotherapy and NOAC plus antiplatelet combination therapy using real-world data.</p><p><strong>Methods: </strong>Between 2015 and 2020, patients with AF who had received NOACs beyond one year after coronary revascularization were enrolled from Korean national insurance data. We emulated a pragmatic sequence of trials between the NOAC monotherapy and the antiplatelet combination therapy followed by propensity score matching. The primary endpoint was major adverse cardiac and cerebrovascular events (MACCEs), a composite of all-cause death, myocardial infarction, and stroke.</p><p><strong>Results: </strong>Among 206,407 person-trials from 4,465 individuals, we compared 3,275 pairs of the monotherapy and the matched combination therapy. During a median follow-up of 1.24 years, the incidence rate of MACCE was 19.4% and 20.0% per patient-year in the monotherapy group and the antiplatelet combination group, respectively (hazard ratio [HR], 0.96; 95% confidence interval [CI], 0.88-1.05; <i>P</i> = 0.422). Compared with the antiplatelet combination group, the monotherapy group had a significantly lower incidence rate of major bleeding, defined as intracranial bleeding or gastrointestinal bleeding requiring hospitalization (2.8% vs. 3.6% per patient-year; HR, 0.78; 95% CI, 0.62-0.97; <i>P</i> = 0.024).</p><p><strong>Conclusion: </strong>As an antithrombotic therapy for AF beyond one year after coronary revascularization, NOAC monotherapy was associated with a similar risk of MACCE and a lower risk of major bleeding compared to NOAC plus antiplatelet combination therapy.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11196858/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141446355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular Safety of COVID-19 Vaccination in Patients With Cancer: A Self-Controlled Case Series Study in Korea. 癌症患者接种 COVID-19 疫苗的心血管安全性:韩国的一项自我对照病例系列研究。
IF 3 3区 医学 Q1 Medicine Pub Date : 2024-06-24 DOI: 10.3346/jkms.2024.39.e190
Ji Hwa Ryu, Ahhyung Choi, Jieun Woo, Hyesung Lee, Jinkwon Kim, Joonsang Yoo, Ju-Young Shin

Background: Cancer patients have an increased risk of cardiovascular outcomes and are susceptible to coronavirus disease 2019 (COVID-19) infection. We aimed to assess the cardiovascular safety of COVID-19 vaccination for cancer patients in South Korea.

Methods: We conducted a self-controlled case series study using the K-COV-N cohort (2018-2021). Patients with cancer aged 12 years or older who experienced cardiovascular outcomes were identified. Cardiovascular outcomes were defined as myocardial infarction, stroke, venous thromboembolism (VTE), myocarditis, or pericarditis, and the risk period was 0-28 days after receiving each dose of COVID-19 vaccines. A conditional Poisson regression model was used to calculate the incidence rate ratio (IRR) with 95% confidence interval (CI).

Results: Among 318,105 patients with cancer, 4,754 patients with cardiovascular outcomes were included. The overall cardiovascular risk was not increased (adjusted IRR, 0.99 [95% CI, 0.90-1.08]) during the whole risk period. The adjusted IRRs of total cardiovascular outcomes during the whole risk period according to the vaccine type were 1.07 (95% CI, 0.95-1.21) in the mRNA vaccine subgroup, 0.99 (95% CI, 0.83-1.19) in the ChAdOx1 nCoV-19 vaccine subgroup, and 0.86 (95% CI, 0.68-1.10) in the mix-matched vaccination subgroup. However, in the analysis of individual outcome, the adjusted IRR of myocarditis was increased to 11.71 (95% CI, 5.88-23.35) during the whole risk period. In contrast, no increased risk was observed for other outcomes, such as myocardial infarction, stroke, VTE, and pericarditis.

Conclusion: For cancer patients, COVID-19 vaccination demonstrated an overall safe profile in terms of cardiovascular outcomes. However, caution is required as an increased risk of myocarditis following COVID-19 vaccination was observed in this study.

背景:癌症患者发生心血管疾病的风险增加,并且容易感染冠状病毒病 2019 (COVID-19)。我们旨在评估韩国癌症患者接种 COVID-19 疫苗的心血管安全性:我们利用 K-COV-N 队列(2018-2021 年)开展了一项自我对照病例系列研究。我们对年龄在 12 岁或以上、出现心血管后果的癌症患者进行了鉴定。心血管后果被定义为心肌梗死、中风、静脉血栓栓塞(VTE)、心肌炎或心包炎,风险期为接种每剂COVID-19疫苗后的0-28天。采用条件泊松回归模型计算发病率比(IRR)及95%置信区间(CI):结果:在 318 105 名癌症患者中,有 4 754 名患者出现心血管疾病。在整个风险期内,总体心血管风险没有增加(调整后的内部风险率为 0.99 [95% CI, 0.90-1.08])。在整个风险期内,根据疫苗类型调整后的心血管总风险IRR在mRNA疫苗亚组为1.07(95% CI,0.95-1.21),在ChAdOx1 nCoV-19疫苗亚组为0.99(95% CI,0.83-1.19),在混合匹配疫苗亚组为0.86(95% CI,0.68-1.10)。然而,在对个别结果的分析中,在整个风险期内,心肌炎的调整后内部风险率增加到 11.71(95% CI,5.88-23.35)。相比之下,心肌梗死、中风、VTE和心包炎等其他结果的风险并没有增加:结论:对于癌症患者来说,COVID-19 疫苗接种在心血管后果方面总体安全。结论:对于癌症患者来说,COVID-19 疫苗接种在心血管后果方面表现出总体安全的特征,但需要谨慎,因为在本研究中观察到接种 COVID-19 疫苗后心肌炎的风险增加。
{"title":"Cardiovascular Safety of COVID-19 Vaccination in Patients With Cancer: A Self-Controlled Case Series Study in Korea.","authors":"Ji Hwa Ryu, Ahhyung Choi, Jieun Woo, Hyesung Lee, Jinkwon Kim, Joonsang Yoo, Ju-Young Shin","doi":"10.3346/jkms.2024.39.e190","DOIUrl":"10.3346/jkms.2024.39.e190","url":null,"abstract":"<p><strong>Background: </strong>Cancer patients have an increased risk of cardiovascular outcomes and are susceptible to coronavirus disease 2019 (COVID-19) infection. We aimed to assess the cardiovascular safety of COVID-19 vaccination for cancer patients in South Korea.</p><p><strong>Methods: </strong>We conducted a self-controlled case series study using the K-COV-N cohort (2018-2021). Patients with cancer aged 12 years or older who experienced cardiovascular outcomes were identified. Cardiovascular outcomes were defined as myocardial infarction, stroke, venous thromboembolism (VTE), myocarditis, or pericarditis, and the risk period was 0-28 days after receiving each dose of COVID-19 vaccines. A conditional Poisson regression model was used to calculate the incidence rate ratio (IRR) with 95% confidence interval (CI).</p><p><strong>Results: </strong>Among 318,105 patients with cancer, 4,754 patients with cardiovascular outcomes were included. The overall cardiovascular risk was not increased (adjusted IRR, 0.99 [95% CI, 0.90-1.08]) during the whole risk period. The adjusted IRRs of total cardiovascular outcomes during the whole risk period according to the vaccine type were 1.07 (95% CI, 0.95-1.21) in the mRNA vaccine subgroup, 0.99 (95% CI, 0.83-1.19) in the ChAdOx1 nCoV-19 vaccine subgroup, and 0.86 (95% CI, 0.68-1.10) in the mix-matched vaccination subgroup. However, in the analysis of individual outcome, the adjusted IRR of myocarditis was increased to 11.71 (95% CI, 5.88-23.35) during the whole risk period. In contrast, no increased risk was observed for other outcomes, such as myocardial infarction, stroke, VTE, and pericarditis.</p><p><strong>Conclusion: </strong>For cancer patients, COVID-19 vaccination demonstrated an overall safe profile in terms of cardiovascular outcomes. However, caution is required as an increased risk of myocarditis following COVID-19 vaccination was observed in this study.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11196855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141446385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of the Early COVID-19 Pandemic on Emergency Department Visits of Adult Cancer Patients With Fever or Respiratory Symptoms: A Korean Nationwide Population-Based Study, 2016-2020. 早期 COVID-19 大流行对伴有发热或呼吸道症状的成年癌症患者急诊就诊的影响:一项基于韩国全国人口的研究,2016-2020 年。
IF 4.5 3区 医学 Q1 Medicine Pub Date : 2024-06-17 DOI: 10.3346/jkms.2024.39.e187
Kyung Shin Lee, Ho Kyung Sung, Youn Young Choi, Changwoo Han, Hye Sook Min

Background: We performed a nationwide analysis to evaluate the impact of the early coronavirus disease 2019 (COVID-19) pandemic on emergency department (ED) visits by adult cancer patients having COVID-like symptoms.

Methods: We analyzed the National Emergency Department Information System (NEDIS) data on ED visits by adult cancer patients who presented with chief complaints of fever or respiratory symptoms (FRS) indicative of COVID-19, from 2016 to 2020. An interrupted time series analysis with a quasi-Poisson regression model was performed, adjusting for seasonality and time, to evaluate whether underlying trends for monthly ED visits and the in-hospital mortality rate (%) per month changed with the pandemic among these patients. We also estimated the adjusted odds ratio (aOR) of in-hospital deaths among cancer patients using multivariable logistic regression analysis.

Results: ED visits by cancer patients with FRS decreased during the COVID-19 pandemic (relative risk [RR] with 95% confidence interval [CI]: slope change, 0.99 [0.98-1.00] and step change, 0.84 [0.76-0.92]). However, the in-hospital mortality rate (%) for these patients was increased (slope change, 1.14 [1.04-1.25] and step change, 0.99 [0.98-1.01]). Factors such as urgent triage status, ambulance use, and treatment in hospitals with fewer than 300 staffed beds significantly contributed to increased aOR of in-hospital deaths during the COVID-19 pandemic compared to the pre-pandemic period.

Conclusion: Further studies are needed to highlight the importance of ED service preparation in planning and managing resources for cancer patients during future pandemics.

背景:我们在全国范围内开展了一项分析,评估2019年早期冠状病毒病(COVID-19)大流行对出现COVID类似症状的成年癌症患者急诊就诊的影响:我们在全国范围内开展了一项分析,以评估2019年早期冠状病毒病(COVID-19)大流行对出现COVID类似症状的成年癌症患者到急诊科(ED)就诊的影响:我们分析了全国急诊科信息系统(NEDIS)2016 年至 2020 年期间主诉发热或呼吸道症状(FRS)提示 COVID-19 的成年癌症患者的急诊科就诊数据。我们利用准泊松回归模型进行了间断时间序列分析,并对季节性和时间进行了调整,以评估这些患者的每月急诊就诊率和每月院内死亡率(%)的基本趋势是否随大流行而发生变化。我们还利用多变量逻辑回归分析估算了癌症患者院内死亡的调整后几率比(aOR):结果:在 COVID-19 大流行期间,FRS 癌症患者的急诊就诊率有所下降(相对风险 [RR],95% 置信区间 [CI]:斜率变化为 0.99 [0.98-1.00],阶跃变化为 0.84 [0.76-0.92])。然而,这些患者的院内死亡率(%)却有所上升(斜率变化为 1.14 [1.04-1.25],台阶变化为 0.99 [0.98-1.01])。COVID-19大流行期间,与大流行前相比,紧急分流状态、救护车的使用以及在人员配备床位少于300张的医院接受治疗等因素显著增加了院内死亡的aOR:结论:需要开展进一步研究,以强调在未来大流行期间,急诊室服务准备工作在规划和管理癌症患者资源方面的重要性。
{"title":"Impact of the Early COVID-19 Pandemic on Emergency Department Visits of Adult Cancer Patients With Fever or Respiratory Symptoms: A Korean Nationwide Population-Based Study, 2016-2020.","authors":"Kyung Shin Lee, Ho Kyung Sung, Youn Young Choi, Changwoo Han, Hye Sook Min","doi":"10.3346/jkms.2024.39.e187","DOIUrl":"10.3346/jkms.2024.39.e187","url":null,"abstract":"<p><strong>Background: </strong>We performed a nationwide analysis to evaluate the impact of the early coronavirus disease 2019 (COVID-19) pandemic on emergency department (ED) visits by adult cancer patients having COVID-like symptoms.</p><p><strong>Methods: </strong>We analyzed the National Emergency Department Information System (NEDIS) data on ED visits by adult cancer patients who presented with chief complaints of fever or respiratory symptoms (FRS) indicative of COVID-19, from 2016 to 2020. An interrupted time series analysis with a quasi-Poisson regression model was performed, adjusting for seasonality and time, to evaluate whether underlying trends for monthly ED visits and the in-hospital mortality rate (%) per month changed with the pandemic among these patients. We also estimated the adjusted odds ratio (aOR) of in-hospital deaths among cancer patients using multivariable logistic regression analysis.</p><p><strong>Results: </strong>ED visits by cancer patients with FRS decreased during the COVID-19 pandemic (relative risk [RR] with 95% confidence interval [CI]: slope change, 0.99 [0.98-1.00] and step change, 0.84 [0.76-0.92]). However, the in-hospital mortality rate (%) for these patients was increased (slope change, 1.14 [1.04-1.25] and step change, 0.99 [0.98-1.01]). Factors such as urgent triage status, ambulance use, and treatment in hospitals with fewer than 300 staffed beds significantly contributed to increased aOR of in-hospital deaths during the COVID-19 pandemic compared to the pre-pandemic period.</p><p><strong>Conclusion: </strong>Further studies are needed to highlight the importance of ED service preparation in planning and managing resources for cancer patients during future pandemics.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141419469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Effectiveness of Personal Sound Amplification Products Versus Hearing Aids for Unilateral Hearing Loss: A Prospective Randomized Crossover Trial. 个人扩音产品与助听器治疗单侧听力损失的效果比较:一项前瞻性随机交叉试验。
IF 3 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-06-17 DOI: 10.3346/jkms.2024.39.e179
Min Su Kim, Kwan Ho Kim, Goun Choe, Yong-Ho Park

Background: This study compared hearing outcomes with use of personal sound amplification products (PSAPs) and hearing aids (HAs) in patients with moderate to moderately severe unilateral hearing loss.

Methods: Thirty-nine participants were prospectively enrolled, and randomly assigned to use either one HA (basic or premium type) or one PSAP (basic or high-end type) for the first 8 weeks and then the other device for the following 8 weeks. Participants underwent a battery of examinations at three visits, including sound-field audiometry, word recognition score (WRS), speech perception in quiet and in noise, real-ear measurement, and self-report questionnaires.

Results: Functional gain was significantly higher with HAs across all frequencies (P < 0.001). While both PSAPs and HAs improved WRS from the unaided condition, HAs were superior to PSAPs. The speech recognition threshold in quiet conditions and signal-to-noise ratio in noisy conditions were significantly lower in the HA-aided condition than in the PSAP-aided condition, and in the PSAP-aided condition than in the unaided condition. Subjective satisfaction also favored HAs than PSAPs in questionnaires, Abbreviated Profile of Hearing Aid Benefit, International Outcome Inventory for Hearing Aids, and Host Institutional Questionnaire.

Conclusion: While PSAPs provide some benefit for moderate to moderately severe unilateral hearing loss, HAs are more effective. This underscores the potential role of PSAPs as an accessible, affordable first-line intervention in hearing rehabilitation, particularly for individuals facing challenges in accessing conventional HAs.

背景:本研究比较了中度和中重度单侧听力损失患者使用个人声音放大产品(PSAP)和助听器(HA)的听力效果:本研究比较了中度至中重度单侧听力损失患者使用个人扩音产品(PSAP)和助听器(HA)的听力效果:39名参与者接受了前瞻性注册,并被随机分配在前8周使用一种HA(基本型或高级型)或一种PSAP(基本型或高级型),然后在随后的8周使用另一种设备。受试者在三次就诊时接受了一系列检查,包括声场测听、单词识别评分(WRS)、安静和噪音环境下的言语感知、实耳测量和自我报告问卷:在所有频率上,助听器的功能增益都明显更高(P < 0.001)。虽然助听器和助听器都能改善无助听条件下的 WRS,但助听器优于助听器。在静音条件下,HA 辅助条件下的语音识别阈值和嘈杂条件下的信噪比明显低于 PSAP 辅助条件,而 PSAP 辅助条件下的语音识别阈值和信噪比也明显低于无辅助条件。在问卷调查、助听器益处简明档案、助听器国际结果调查表和东道机构问卷调查中,主观满意度也是助听器优于PSAP:结论:虽然 PSAPs 对中度至中重度单侧听力损失有一定疗效,但助听器更有效。这凸显了 PSAPs 作为听力康复中可获得、可负担的一线干预措施的潜在作用,尤其是对于在获得传统助听器方面面临挑战的个人而言。
{"title":"Comparative Effectiveness of Personal Sound Amplification Products Versus Hearing Aids for Unilateral Hearing Loss: A Prospective Randomized Crossover Trial.","authors":"Min Su Kim, Kwan Ho Kim, Goun Choe, Yong-Ho Park","doi":"10.3346/jkms.2024.39.e179","DOIUrl":"10.3346/jkms.2024.39.e179","url":null,"abstract":"<p><strong>Background: </strong>This study compared hearing outcomes with use of personal sound amplification products (PSAPs) and hearing aids (HAs) in patients with moderate to moderately severe unilateral hearing loss.</p><p><strong>Methods: </strong>Thirty-nine participants were prospectively enrolled, and randomly assigned to use either one HA (basic or premium type) or one PSAP (basic or high-end type) for the first 8 weeks and then the other device for the following 8 weeks. Participants underwent a battery of examinations at three visits, including sound-field audiometry, word recognition score (WRS), speech perception in quiet and in noise, real-ear measurement, and self-report questionnaires.</p><p><strong>Results: </strong>Functional gain was significantly higher with HAs across all frequencies (<i>P</i> < 0.001). While both PSAPs and HAs improved WRS from the unaided condition, HAs were superior to PSAPs. The speech recognition threshold in quiet conditions and signal-to-noise ratio in noisy conditions were significantly lower in the HA-aided condition than in the PSAP-aided condition, and in the PSAP-aided condition than in the unaided condition. Subjective satisfaction also favored HAs than PSAPs in questionnaires, Abbreviated Profile of Hearing Aid Benefit, International Outcome Inventory for Hearing Aids, and Host Institutional Questionnaire.</p><p><strong>Conclusion: </strong>While PSAPs provide some benefit for moderate to moderately severe unilateral hearing loss, HAs are more effective. This underscores the potential role of PSAPs as an accessible, affordable first-line intervention in hearing rehabilitation, particularly for individuals facing challenges in accessing conventional HAs.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141419468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Outcomes of Clipping and Coil Embolization for Ruptured Intracranial Aneurysms Categorized by Region and Hospital Size: A Nationwide Cohort Study in Korea. 按地区和医院规模分类的颅内动脉瘤破裂夹闭术和线圈栓塞术的临床疗效:韩国全国队列研究。
IF 4.5 3区 医学 Q1 Medicine Pub Date : 2024-06-17 DOI: 10.3346/jkms.2024.39.e188
Yu Deok Won, Hyoung Soo Byoun, Tae Won Choi, Sang Hyo Lee, Young Deok Kim, Seung Pil Ban, Jae Seung Bang, O-Ki Kwon, Chang Wan Oh, Si Un Lee

Background: To analyze the outcomes of clipping and coiling for ruptured intracranial aneurysms (RIAs) based on data from the National Health Insurance Service in South Korea, with a focus on variations according to region and hospital size.

Methods: This study analyzed the one-year mortality rates for patients with RIAs who underwent clipping or coiling in 2018. Coiling was further categorized into non-stent assisted coiling (NSAC) and stent assisted coiling (SAC). Hospitals were classified as tertiary referral general hospitals (TRGHs), general hospitals (GHs), or semi-general hospitals (sGHs) based on size. South Korea's administrative districts were divided into 15 regions for analysis.

Results: In 2018, there were 2,194 (33.1%) clipping procedures (TRGH, 985; GH, 827; sGH, 382) and 4,431 (66.9%) coiling procedures (TRGH, 1,642; GH, 2076; sGH, 713) performed for RIAs treatment. Among hospitals performing more than 20 treatments, the one-year mortality rates following clipping or coiling were 11.2% and 16.0%, respectively, with no significant difference observed. However, there was a significant difference in one-year mortality between NSAC and SAC (14.3% vs. 19.5%, P = 0.034), with clipping also showing significantly lower mortality compared to SAC (P = 0.019). No significant differences in other treatment modalities were observed according to hospital size, but clipping at TRGHs had significantly lower mortality than at GHs (P = 0.042). While no significant correlation was found between the number of treatments and outcomes at GHs, at TRGHs, a higher volume of clipping procedures was significantly associated with lower total mortality (P = 0.023) and mortality after clipping (P = 0.022).

Conclusion: Using Korea NHIS data, mortality rates for RIAs showed no significant variation by hospital size due to coiling's prevalence. However, differences in clipping outcomes by hospital size and volume in TRGH highlight the need for national efforts to improve clipping skills and standardization. Additionally, the higher mortality rate with SAC emphasizes the importance of precise indications for its application.

背景:根据韩国国民健康保险服务局的数据,分析颅内动脉瘤破裂(RIA)的剪除和夹闭术的结果,重点关注地区和医院规模的差异:本研究分析了2018年接受夹闭或卷曲术的RIA患者的一年死亡率。卷扎术进一步分为非支架辅助卷扎术(NSAC)和支架辅助卷扎术(SAC)。医院根据规模分为三级转诊综合医院(TRGH)、综合医院(GH)或半综合医院(sGH)。韩国的行政区划分为15个区域进行分析:2018年,共有2194例(33.1%)剪切手术(TRGH,985例;GH,827例;sGH,382例)和4431例(66.9%)卷绕手术(TRGH,1642例;GH,2076例;sGH,713例)用于RIAs治疗。在进行了20次以上治疗的医院中,剪切或卷曲术后的一年死亡率分别为11.2%和16.0%,没有观察到显著差异。然而,NSAC和SAC的一年死亡率有显著差异(14.3% vs. 19.5%,P = 0.034),剪切法的死亡率也显著低于SAC(P = 0.019)。根据医院规模的不同,其他治疗方式也无明显差异,但TRGH的剪切死亡率明显低于GH(P = 0.042)。在普通外科医院,治疗次数与治疗结果之间没有发现明显的相关性,但在全科医院,剪除手术次数越多,总死亡率(P = 0.023)和剪除后死亡率(P = 0.022)就越低:结论:利用韩国 NHIS 数据,RIA 的死亡率并未因医院规模的不同而出现显著差异,这是因为卷曲术的普遍性所致。然而,TRGH中不同规模和数量的医院在剪切结果上存在差异,这凸显了国家在提高剪切技能和标准化方面所做努力的必要性。此外,SAC的死亡率较高,这强调了应用SAC时精确适应症的重要性。
{"title":"Clinical Outcomes of Clipping and Coil Embolization for Ruptured Intracranial Aneurysms Categorized by Region and Hospital Size: A Nationwide Cohort Study in Korea.","authors":"Yu Deok Won, Hyoung Soo Byoun, Tae Won Choi, Sang Hyo Lee, Young Deok Kim, Seung Pil Ban, Jae Seung Bang, O-Ki Kwon, Chang Wan Oh, Si Un Lee","doi":"10.3346/jkms.2024.39.e188","DOIUrl":"10.3346/jkms.2024.39.e188","url":null,"abstract":"<p><strong>Background: </strong>To analyze the outcomes of clipping and coiling for ruptured intracranial aneurysms (RIAs) based on data from the National Health Insurance Service in South Korea, with a focus on variations according to region and hospital size.</p><p><strong>Methods: </strong>This study analyzed the one-year mortality rates for patients with RIAs who underwent clipping or coiling in 2018. Coiling was further categorized into non-stent assisted coiling (NSAC) and stent assisted coiling (SAC). Hospitals were classified as tertiary referral general hospitals (TRGHs), general hospitals (GHs), or semi-general hospitals (sGHs) based on size. South Korea's administrative districts were divided into 15 regions for analysis.</p><p><strong>Results: </strong>In 2018, there were 2,194 (33.1%) clipping procedures (TRGH, 985; GH, 827; sGH, 382) and 4,431 (66.9%) coiling procedures (TRGH, 1,642; GH, 2076; sGH, 713) performed for RIAs treatment. Among hospitals performing more than 20 treatments, the one-year mortality rates following clipping or coiling were 11.2% and 16.0%, respectively, with no significant difference observed. However, there was a significant difference in one-year mortality between NSAC and SAC (14.3% vs. 19.5%, <i>P</i> = 0.034), with clipping also showing significantly lower mortality compared to SAC (<i>P</i> = 0.019). No significant differences in other treatment modalities were observed according to hospital size, but clipping at TRGHs had significantly lower mortality than at GHs (<i>P</i> = 0.042). While no significant correlation was found between the number of treatments and outcomes at GHs, at TRGHs, a higher volume of clipping procedures was significantly associated with lower total mortality (<i>P</i> = 0.023) and mortality after clipping (<i>P</i> = 0.022).</p><p><strong>Conclusion: </strong>Using Korea NHIS data, mortality rates for RIAs showed no significant variation by hospital size due to coiling's prevalence. However, differences in clipping outcomes by hospital size and volume in TRGH highlight the need for national efforts to improve clipping skills and standardization. Additionally, the higher mortality rate with SAC emphasizes the importance of precise indications for its application.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141419443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Arterial Stiffness and Heart Failure With Preserved Ejection Fraction. 动脉僵化与射血分数保留型心力衰竭
IF 3 3区 医学 Q1 Medicine Pub Date : 2024-06-17 DOI: 10.3346/jkms.2024.39.e195
Hack-Lyoung Kim, Sang-Ho Jo

Heart failure with preserved ejection fraction (HFpEF) is prevalent and associated with a poor prognosis, imposing a significant burden on society. Arterial stiffness is increasingly recognized as a crucial factor in the pathophysiology of HFpEF, affecting diagnosis, management, and prognosis. As a hallmark of vascular aging, arterial stiffness contributes to increased afterload on the left ventricle (LV), leading to diastolic dysfunction, a key feature of HFpEF. Elevated arterial stiffness is linked with common cardiovascular risk factors in HFpEF, such as hypertension, diabetes and obesity, exacerbating the progression of disease. Studies have demonstrated that patients with HFpEF exhibit significantly higher levels of arterial stiffness compared to those without HFpEF, highlighting the value of arterial stiffness measurements as both diagnostic and prognostic tools. Moreover, interventions aimed at reducing arterial stiffness, whether through pharmacological therapies or lifestyle modifications, have shown potential in improving LV diastolic function and patient outcomes. Despite these advancements, the precise mechanisms by which arterial stiffness contributes to HFpEF are still not fully understood, necessitating the need for further research.

射血分数保留型心力衰竭(HFpEF)发病率高、预后差,给社会造成了沉重负担。动脉僵化越来越被认为是高射血分数心力衰竭病理生理学中的一个关键因素,影响着诊断、管理和预后。作为血管老化的标志,动脉僵化会导致左心室(LV)后负荷增加,从而导致舒张功能障碍,这是高频心衰的一个主要特征。动脉僵化的加剧与高血压、糖尿病和肥胖等高频心衰患者常见的心血管风险因素有关,从而加剧了疾病的进展。研究表明,与非高频低氧血症患者相比,高频低氧血症患者的动脉僵化程度明显更高,这凸显了动脉僵化测量作为诊断和预后工具的价值。此外,旨在降低动脉僵化的干预措施,无论是通过药物疗法还是通过改变生活方式,都显示出改善左心室舒张功能和患者预后的潜力。尽管取得了这些进展,但动脉僵化导致高频心衰的确切机制仍未完全明了,因此有必要开展进一步的研究。
{"title":"Arterial Stiffness and Heart Failure With Preserved Ejection Fraction.","authors":"Hack-Lyoung Kim, Sang-Ho Jo","doi":"10.3346/jkms.2024.39.e195","DOIUrl":"10.3346/jkms.2024.39.e195","url":null,"abstract":"<p><p>Heart failure with preserved ejection fraction (HFpEF) is prevalent and associated with a poor prognosis, imposing a significant burden on society. Arterial stiffness is increasingly recognized as a crucial factor in the pathophysiology of HFpEF, affecting diagnosis, management, and prognosis. As a hallmark of vascular aging, arterial stiffness contributes to increased afterload on the left ventricle (LV), leading to diastolic dysfunction, a key feature of HFpEF. Elevated arterial stiffness is linked with common cardiovascular risk factors in HFpEF, such as hypertension, diabetes and obesity, exacerbating the progression of disease. Studies have demonstrated that patients with HFpEF exhibit significantly higher levels of arterial stiffness compared to those without HFpEF, highlighting the value of arterial stiffness measurements as both diagnostic and prognostic tools. Moreover, interventions aimed at reducing arterial stiffness, whether through pharmacological therapies or lifestyle modifications, have shown potential in improving LV diastolic function and patient outcomes. Despite these advancements, the precise mechanisms by which arterial stiffness contributes to HFpEF are still not fully understood, necessitating the need for further research.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141419442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Late Parasitological Failure and Subsequent Isolated Gametocytemia of Uncomplicated Plasmodium falciparum Malaria in a Returned Traveler From Ghana, 2023. 2023 年一名加纳归国旅行者未并发恶性疟原虫疟疾的晚期寄生虫学衰竭和随后的分离配子细胞血症》(Late Parasitological Failure and Subsequent Isolated Gametocytemia of Uncomcompllicated Plasmodium falciparum Malaria in a Returned Traveler from Ghana, 2023.
IF 4.5 3区 医学 Q1 Medicine Pub Date : 2024-06-10 DOI: 10.3346/jkms.2024.39.e186
Jiyeon Bae, Jeong-Han Kim, Seunghwan Kim, Jungwon Huh, Hee Jung Choi

Herein, we report a case of uncomplicated falciparum malaria with late parasitological failure in a 45-year-old businessman returning from Ghana. The patient visited the emergency department with high fever, headache, and dizziness. He traveled without antimalarial chemoprophylaxis. Laboratory tests led to the diagnosis of uncomplicated falciparum malaria with an initial density of 37,669 parasites per μL of blood (p/μL). The patient was treated with intravenous artesunate followed by atovaquone/proguanil. He was discharged with improved condition and decreased parasite density of 887 p/μL. However, at follow-up, parasite density increased to 7,630 p/μL despite the absence of any symptoms. Suspecting treatment failure, the patient was administered intravenous artesunate and doxycycline for seven days and then artemether/lumefantrine for three days. Blood smear was negative for asexual parasitemia after re-treatment but positive for gametocytemia until day 101 from the initial diagnosis. Overall, this case highlights the risk of late parasitological failure in patients with imported uncomplicated falciparum malaria.

在此,我们报告了一例无并发症恶性疟原虫疟疾病例,患者是一名从加纳回国的 45 岁商人,寄生虫学晚期衰竭。患者因高烧、头痛和头晕到急诊科就诊。他在旅行途中没有服用抗疟药物。实验室检查结果诊断为无并发症恶性疟原虫疟疾,初始寄生虫密度为每微升血液中 37,669 个寄生虫(p/μL)。患者接受了青蒿琥酯静脉注射治疗,随后又接受了阿托伐醌/丙谷尼治疗。他出院时病情有所好转,寄生虫密度下降到 887 p/μL。然而,在随访时,尽管没有任何症状,寄生虫密度却上升到 7,630 p/μL。由于怀疑治疗失败,该患者接受了为期七天的青蒿琥酯和多西环素静脉注射,然后又接受了为期三天的蒿甲醚/卢曼蒽林静脉注射。重新治疗后,血涂片无性寄生虫血症呈阴性,但配子细胞血症呈阳性,直到最初诊断的第 101 天。总之,该病例突出显示了输入性无并发症恶性疟原虫疟疾患者后期寄生虫学失败的风险。
{"title":"Late Parasitological Failure and Subsequent Isolated Gametocytemia of Uncomplicated <i>Plasmodium falciparum</i> Malaria in a Returned Traveler From Ghana, 2023.","authors":"Jiyeon Bae, Jeong-Han Kim, Seunghwan Kim, Jungwon Huh, Hee Jung Choi","doi":"10.3346/jkms.2024.39.e186","DOIUrl":"10.3346/jkms.2024.39.e186","url":null,"abstract":"<p><p>Herein, we report a case of uncomplicated falciparum malaria with late parasitological failure in a 45-year-old businessman returning from Ghana. The patient visited the emergency department with high fever, headache, and dizziness. He traveled without antimalarial chemoprophylaxis. Laboratory tests led to the diagnosis of uncomplicated falciparum malaria with an initial density of 37,669 parasites per μL of blood (p/μL). The patient was treated with intravenous artesunate followed by atovaquone/proguanil. He was discharged with improved condition and decreased parasite density of 887 p/μL. However, at follow-up, parasite density increased to 7,630 p/μL despite the absence of any symptoms. Suspecting treatment failure, the patient was administered intravenous artesunate and doxycycline for seven days and then artemether/lumefantrine for three days. Blood smear was negative for asexual parasitemia after re-treatment but positive for gametocytemia until day 101 from the initial diagnosis. Overall, this case highlights the risk of late parasitological failure in patients with imported uncomplicated falciparum malaria.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11164651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact and Implications of the Flexner Report on Medical Education in Korea. 弗莱克斯纳报告》对韩国医学教育的影响和意义。
IF 4.5 3区 医学 Q1 Medicine Pub Date : 2024-06-10 DOI: 10.3346/jkms.2024.39.e182
Hyun Bae Yoon, Sun Jung Myung

The recent debate surrounding the expansion of enrollment in Korean medical schools has reignited interest in the Flexner Report, published in the United States in 1910. Historically, medical education in the United States transitioned from small proprietary schools to university-affiliated institutions, emphasizing basic science and clinical experience. The Flexner Report advocated for scientific medicine and led to significant reforms in medical education, including standardization of curricula and strengthened admission requirements. The influence of this report extended to Korean medical education, shaping its curriculum, accreditation system, and emphasis on academic excellence. The expansion of medical school enrollment has led to a crucial dilemma. Should we prioritize the training of physicians who provide practical medical services or continue to emphasize academic medicine as we do now? There has been insufficient discussion of the individualized curricula, necessary investments, and societal efforts to accommodate these changes. It is imperative to move beyond mere enrollment expansion debates and collectively determine the future trajectory of Korean medical education, devising actionable plans to achieve overarching goals.

最近,围绕韩国医学院扩招的争论再次激起了人们对美国 1910 年发表的《弗莱克斯纳报告》的兴趣。历史上,美国的医学教育从小型专有学校过渡到大学附属机构,强调基础科学和临床经验。弗莱克斯纳报告》倡导科学医学,促成了医学教育的重大改革,包括课程标准化和强化入学要求。该报告的影响延伸到韩国的医学教育,塑造了韩国的课程设置、评审制度和对学术卓越性的强调。医学院招生规模的扩大导致了一个至关重要的难题。我们应该优先培养提供实际医疗服务的医生,还是像现在这样继续强调学术医学?对于适应这些变化所需的个性化课程、必要的投资和社会努力,我们还没有进行充分的讨论。当务之急是超越单纯的扩招辩论,共同确定韩国医学教育的未来发展轨迹,制定可行的计划以实现总体目标。
{"title":"The Impact and Implications of the Flexner Report on Medical Education in Korea.","authors":"Hyun Bae Yoon, Sun Jung Myung","doi":"10.3346/jkms.2024.39.e182","DOIUrl":"10.3346/jkms.2024.39.e182","url":null,"abstract":"<p><p>The recent debate surrounding the expansion of enrollment in Korean medical schools has reignited interest in the Flexner Report, published in the United States in 1910. Historically, medical education in the United States transitioned from small proprietary schools to university-affiliated institutions, emphasizing basic science and clinical experience. The Flexner Report advocated for scientific medicine and led to significant reforms in medical education, including standardization of curricula and strengthened admission requirements. The influence of this report extended to Korean medical education, shaping its curriculum, accreditation system, and emphasis on academic excellence. The expansion of medical school enrollment has led to a crucial dilemma. Should we prioritize the training of physicians who provide practical medical services or continue to emphasize academic medicine as we do now? There has been insufficient discussion of the individualized curricula, necessary investments, and societal efforts to accommodate these changes. It is imperative to move beyond mere enrollment expansion debates and collectively determine the future trajectory of Korean medical education, devising actionable plans to achieve overarching goals.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11164650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Skeletal-Related Events in Patients With Multiple Myeloma: A Comprehensive Retrospective Cohort Study. 多发性骨髓瘤患者的骨骼相关事件:一项全面的回顾性队列研究
IF 4.5 3区 医学 Q1 Medicine Pub Date : 2024-06-10 DOI: 10.3346/jkms.2024.39.e175
Ji Yun Lee, Ju-Hyun Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Jong Seok Lee, Soo-Mee Bang

Background: Multiple myeloma (MM) patients are at risk of skeletal-related events (SREs) like spinal cord compression, pathologic fractures, bone surgery, and radiation to bone. Real-world data regarding SREs in MM are limited.

Methods: We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service (HIRA) database from 2007 to 2018.

Results: Over a 12-year study period, we identified 6,717 patients who developed symptomatic MM. After a median follow-up of 35.1 months (interquartile range [IQR], 20.8-58.2 months), 43.6% of these patients experienced SREs, and 39.6% had four or more SREs. One in five patients (20.0%) experienced pathologic fractures within the first year of follow-up. The median time to first SRE was 9.6 months (IQR, 1.2-25.8 months), with 3.0 months in the group with prior SREs and 19.8 months in the group without prior SREs. During follow-up, 78.5% of patients received bisphosphonates. Multiple logistic regression analysis revealed several factors associated with an increased risk of SREs, including being female (odds ratio [OR], 1.44), aged 50 or older (OR, 1.87), having cerebrovascular disease (OR, 1.34), undergoing first-line chemotherapy regimens not containing bortezomib or lenalidomide (OR, 1.49), and being in the group with prior SREs and bisphosphonate use (OR, 5.63), compared to the group without prior SREs and without bisphosphonate use.

Conclusion: This population-based study is the first to report the incidence and risk factors of SREs in Korean MM patients, which can be used to assess their bone health.

背景:多发性骨髓瘤(MM)患者有发生骨骼相关事件(SRE)的风险,如脊髓压迫、病理性骨折、骨外科手术和骨放射。有关 MM SRE 的实际数据非常有限:我们利用韩国健康保险审查和评估服务(HIRA)数据库,在 2007 年至 2018 年期间开展了一项大型、回顾性、全国性队列研究:在12年的研究期间,我们发现了6717名出现症状的MM患者。在中位随访 35.1 个月(四分位数间距 [IQR],20.8-58.2 个月)后,43.6% 的患者出现了 SRE,39.6% 的患者出现了四次或四次以上的 SRE。每五名患者中就有一名(20.0%)在随访第一年内发生病理性骨折。发生首次SRE的中位时间为9.6个月(IQR,1.2-25.8个月),其中发生过SRE的患者为3.0个月,未发生过SRE的患者为19.8个月。在随访期间,78.5%的患者接受了双磷酸盐治疗。多元逻辑回归分析表明,女性(几率比 [OR],1.44)、50 岁或以上(OR,1.87)、患有脑血管疾病(OR,1.34)、接受不含硼替佐米或来那度胺的一线化疗方案(OR,1.49),以及与无既往SRE和未使用双膦酸盐组相比,属于既往SRE和使用双膦酸盐组(OR,5.63):这项基于人群的研究首次报告了韩国 MM 患者 SRE 的发生率和风险因素,可用于评估他们的骨骼健康状况。
{"title":"Skeletal-Related Events in Patients With Multiple Myeloma: A Comprehensive Retrospective Cohort Study.","authors":"Ji Yun Lee, Ju-Hyun Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Jong Seok Lee, Soo-Mee Bang","doi":"10.3346/jkms.2024.39.e175","DOIUrl":"10.3346/jkms.2024.39.e175","url":null,"abstract":"<p><strong>Background: </strong>Multiple myeloma (MM) patients are at risk of skeletal-related events (SREs) like spinal cord compression, pathologic fractures, bone surgery, and radiation to bone. Real-world data regarding SREs in MM are limited.</p><p><strong>Methods: </strong>We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service (HIRA) database from 2007 to 2018.</p><p><strong>Results: </strong>Over a 12-year study period, we identified 6,717 patients who developed symptomatic MM. After a median follow-up of 35.1 months (interquartile range [IQR], 20.8-58.2 months), 43.6% of these patients experienced SREs, and 39.6% had four or more SREs. One in five patients (20.0%) experienced pathologic fractures within the first year of follow-up. The median time to first SRE was 9.6 months (IQR, 1.2-25.8 months), with 3.0 months in the group with prior SREs and 19.8 months in the group without prior SREs. During follow-up, 78.5% of patients received bisphosphonates. Multiple logistic regression analysis revealed several factors associated with an increased risk of SREs, including being female (odds ratio [OR], 1.44), aged 50 or older (OR, 1.87), having cerebrovascular disease (OR, 1.34), undergoing first-line chemotherapy regimens not containing bortezomib or lenalidomide (OR, 1.49), and being in the group with prior SREs and bisphosphonate use (OR, 5.63), compared to the group without prior SREs and without bisphosphonate use.</p><p><strong>Conclusion: </strong>This population-based study is the first to report the incidence and risk factors of SREs in Korean MM patients, which can be used to assess their bone health.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11164652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fine-Scale Spatial Prediction on the Risk of Plasmodium vivax Infection in the Republic of Korea. 关于大韩民国间日疟原虫感染风险的精细空间预测。
IF 4.5 3区 医学 Q1 Medicine Pub Date : 2024-06-10 DOI: 10.3346/jkms.2024.39.e176
Kyung-Duk Min, Yae Jee Baek, Kyungwon Hwang, Na-Ri Shin, So-Dam Lee, Hyesu Kan, Joon-Sup Yeom

Background: Malaria elimination strategies in the Republic of Korea (ROK) have decreased malaria incidence but face challenges due to delayed case detection and response. To improve this, machine learning models for predicting malaria, focusing on high-risk areas, have been developed.

Methods: The study targeted the northern region of ROK, near the demilitarized zone, using a 1-km grid to identify areas for prediction. Grid cells without residential buildings were excluded, leaving 8,425 cells. The prediction was based on whether at least one malaria case was reported in each grid cell per month, using spatial data of patient locations. Four algorithms were used: gradient boosted (GBM), generalized linear (GLM), extreme gradient boosted (XGB), and ensemble models, incorporating environmental, sociodemographic, and meteorological data as predictors. The models were trained with data from May to October (2019-2021) and tested with data from May to October 2022. Model performance was evaluated using the area under the receiver operating characteristic curve (AUROC).

Results: The AUROC of the prediction models performed excellently (GBM = 0.9243, GLM = 0.9060, XGB = 0.9180, and ensemble model = 0.9301). Previous malaria risk, population size, and meteorological factors influenced the model most in GBM and XGB.

Conclusion: Machine-learning models with properly preprocessed malaria case data can provide reliable predictions. Additional predictors, such as mosquito density, should be included in future studies to improve the performance of models.

背景:大韩民国(ROK)的消除疟疾战略降低了疟疾发病率,但由于病例检测和响应延迟而面临挑战。为了改善这一状况,韩国开发了用于预测疟疾的机器学习模型,重点关注高风险地区:研究以非军事区附近的韩国北部地区为目标,使用 1 公里网格来确定预测区域。没有居民楼的网格单元被排除在外,剩下 8425 个单元。预测的依据是每个网格单元每月是否至少报告一例疟疾病例,使用的是患者位置的空间数据。使用了四种算法:梯度提升(GBM)、广义线性(GLM)、极端梯度提升(XGB)和集合模型,将环境、社会人口和气象数据作为预测因子。这些模型使用 2019-2021 年 5 月至 10 月的数据进行训练,并使用 2022 年 5 月至 10 月的数据进行测试。使用接收者工作特征曲线下面积(AUROC)对模型性能进行评估:预测模型的 AUROC 表现优异(GBM = 0.9243、GLM = 0.9060、XGB = 0.9180 和集合模型 = 0.9301)。以前的疟疾风险、人口数量和气象因素对 GBM 和 XGB 模型的影响最大:结论:经过适当预处理的疟疾病例数据的机器学习模型可以提供可靠的预测。在未来的研究中应加入更多的预测因素,如蚊子密度,以提高模型的性能。
{"title":"Fine-Scale Spatial Prediction on the Risk of <i>Plasmodium vivax</i> Infection in the Republic of Korea.","authors":"Kyung-Duk Min, Yae Jee Baek, Kyungwon Hwang, Na-Ri Shin, So-Dam Lee, Hyesu Kan, Joon-Sup Yeom","doi":"10.3346/jkms.2024.39.e176","DOIUrl":"10.3346/jkms.2024.39.e176","url":null,"abstract":"<p><strong>Background: </strong>Malaria elimination strategies in the Republic of Korea (ROK) have decreased malaria incidence but face challenges due to delayed case detection and response. To improve this, machine learning models for predicting malaria, focusing on high-risk areas, have been developed.</p><p><strong>Methods: </strong>The study targeted the northern region of ROK, near the demilitarized zone, using a 1-km grid to identify areas for prediction. Grid cells without residential buildings were excluded, leaving 8,425 cells. The prediction was based on whether at least one malaria case was reported in each grid cell per month, using spatial data of patient locations. Four algorithms were used: gradient boosted (GBM), generalized linear (GLM), extreme gradient boosted (XGB), and ensemble models, incorporating environmental, sociodemographic, and meteorological data as predictors. The models were trained with data from May to October (2019-2021) and tested with data from May to October 2022. Model performance was evaluated using the area under the receiver operating characteristic curve (AUROC).</p><p><strong>Results: </strong>The AUROC of the prediction models performed excellently (GBM = 0.9243, GLM = 0.9060, XGB = 0.9180, and ensemble model = 0.9301). Previous malaria risk, population size, and meteorological factors influenced the model most in GBM and XGB.</p><p><strong>Conclusion: </strong>Machine-learning models with properly preprocessed malaria case data can provide reliable predictions. Additional predictors, such as mosquito density, should be included in future studies to improve the performance of models.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11164649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Korean Medical Science
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1